Skip to main content

Advertisement

Table 5 The influence of PRI-2191 or PRI-2205 alone or in combination with 5-FU on intestinal tumor growth, leukocytes and platelets in the blood samples from mice with MC38 colon cancer

From: Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivomouse colon cancer model

Group Tumor weight Leukocytes Platelets N
Mean ± SD [g] TGI [%] %H TGI Effect Mean ± SD [103/μL] Mean ± SD [103/μL]
Control 1.4 ± 1.06     7.7 ± 3.4 684 ± 309 7
PRI-2191 1.26 ± 0.80 4 7.2 ± 1.4 835 ± 170 4
PRI-2205 0.86 ± 0.93 35 8.7 ± 2.3 887 ± 67 6
5-FU 0.28 ± 0.27 79 15.5 ± 5.7 1186 ± 207**c 6
5-FU + PRI-2191 0.08 ±0.15**a,*b 94 80 Synergism 8.6 ± 3.0 1159 ± 254**c 7
5-FU + PRI-2205 0.32 ± 0.25 75 86 Antagonism 7.6 ± 4.1 1046 ± 320 6
  1. TGI, Tumor growth inhibition; %H TGI, Hypothetical tumor growth inhibition; N, Number of mice in group; SD, Standard deviation.
  2. **a P < 0.01 as compared to control; *b P < 0.05 as compared to PRI-2191: Kruskal-Wallis ANOVA (Multiple Comparisons p values (2-tailed)); **c P < 0.01 as compared to control: Tukey HSD.
  3. Mice bearing MC38 tumors implanted i.i. were i.v. injected with 5-FU at a dose of 100 mg/kg/day on days: 8, 15 and/or vitamin D analogs: PRI-2191 at a dose of 1 μg/kg/day or PRI-2205 at a dose of 10 μg/kg/day. Both analogs were administrated s.c., three times a week from days 10 to 20. Mice were sacrificed on day 22 after i.i. transplantation, tumors were weighed and blood was collected.